/
/
Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Un abonnement à JoVE est nécessaire pour voir ce contenu. Connectez-vous ou commencez votre essai gratuit.
1Department of Neurological Surgery, Case Comprehensive Cancer Center,Case Western Reserve University School of Medicine, 2Department of Pathology,Johns Hopkins University, School of Medicine, 3Department of Neurological Surgery, University Hospital-Case Medical Center, Case Comprehensive Cancer Center,Case Western Reserve University School of Medicine
Chapitres
- 00:05Titre
- 01:17Generation of Lentiviral Transcriptional Reporter Cell Lines
- 03:47Subclone Selection, Expansion, and Validation
- 04:47Determination of GFAP:GFP Expression by Flow Cytometry
- 05:58ELDA Self-renewal Assay to Assess Clonogenic Capacity
- 07:01Drug Screen
- 08:27Results: Selection and Drug Screening of Glioblastoma Stem Cell Subclones
- 09:46Conclusion
An efficient screening protocol is presented for the identification of small molecules that promote astroglial differentiation in glioblastoma stem cells (GSCs). The assay is based on a stem cell differentiation reporter whereby the expression of the enhanced GFP (eGFP) is driven by the human GFAP promoter.
Tags
Flow CytometryDrug ScreeningGlioblastoma Stem CellsCellular DifferentiationLentivirusReporter ConstructHigh-throughput ScreeningSmall MoleculesAstroglial DifferentiationCancer Stem CellsEhlers-Danlos GlioblastomaCell LineageBloodborne PathogensNeural Stem Cell Growth MediumPolybreneDissociation Reagent
